French oil company funding rotavirus research in Congo

NewsGuard 100/100 Score

"Medical researchers in the Republic of the Congo (Congo-Brazzaville) have been empowered to set their own research priorities through a funding mechanism backed by a French oil company, according to scientists speaking at the second European and Developing Countries Clinical Trials Partnership (EDCTP), in South Africa this month," SciDev.Net reports. "In 2011, the Congolese Foundation for Medical Research signed an agreement with TOTAL, stipulating that the energy giant would fund specific research activities and pay salaries," which "enabled the foundation to set its own research priorities -- a break with the usual funding constraints whereby researchers' priorities are dictated by foreign funding agencies," the news service writes.

"Francine Ntoumi, executive director of the Congolese foundation, says the TOTAL funding is used to run clinical trials on rotavirus vaccines for children in the country," the news service continues, noting, "Rotavirus is ... one of the country's most pressing health challenges." According to the news service, "[t]he partnership between TOTAL and the Congolese Foundation for Medical Research began with a fund of €130,000 (US$165,000)," and "[t]his year, TOTAL has allocated a further around US$190,000 -- almost half the foundation's budget" (Nakkazi, 11/19).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis